A 67-year-old says a new £2,000 device, which is being studied by the NHS, has improved his sleep and allowed him to go back ...

For decades, Parkinson’s disease has been framed as a simple story of dwindling dopamine, a slow erosion of the brain’s ...

Symptoms of Parkinson’s disease, such as tremors and stiffness, can make daily tasks difficult. A new drug has shown promise in alleviating symptoms. Tavapadon, a drug being tested to treat early ...

It’s improving quality of life. Parkinson’s drugs are meant to keep patients in what’s called their “on state,” providing improvement in coordination and stiffness. But as the drugs wear off between ...

Explore dopamine's role in movement and how it challenges long-standing theories about motor control and Parkinson's disease ...

A McGill-led study is challenging a popular theory about how dopamine drives movement, a discovery that could shift how ...

Tavapadon, a drug made by AbbVie to treat Parkinson’s disease, met phase 3 TEMPO-1 trial goals treated early Parkinson’s disease and improved motor skills, the company reported on Thursday. Tavapadon ...

Swiss biotech AC Immune has said that its vaccine-like alpha-synuclein-targeted immunotherapy has shown promise in slowing down the progression of Parkinson's disease.

(WNDU) - Visual hallucinations affect up to 75% of Parkinson’s patients. These visual hallucinations cause them to see things that aren’t really there. Now, there is a medication that targets these ...

A medication developed in the 1950s to treat Parkinson's disease may offer a powerful new tool in the fight against tuberculosis (TB), according to new research from the University of British Columbia ...

Mouse models of GBA1 Parkinson’s disease that are treated with Gain Therapeutics’ clinical-stage drug appear to have better cognitive function and lower disease biomarkers than untreated animals. The ...